Back

Left ventricular dysfunction during mavacamten therapy: risk profiling from a multicenter cohort

11 May 2026 (14:30 - 15:15)
Organised by: Logo
Congress Presentation Part of: Mapping HCM: from functional assessment to optimised therapy Hypertrophic Cardiomyopathy Delegates Premium Access Heart Failure 2026 Heart Failure Association (HFA)

About the speaker

Photo
Mr Julien Lopes

Hospital de Santa Marta, Lisbon (Portugal)

6 More presentations in this session

Presentation thumbnail
Differential effect of antiobstructive therapy on mitral valve morphology in hypertrophic obstructive cardiomyopathy: a comparison of myosin inhibition and PTSMA therapy
Doctor M. Chen (Wuerzburg, DE)
Abstract Slides
Presentation thumbnail
Left atrioventricular coupling index in hypertrophic cardiomyopathy: a new echocardiographic perspective
Associate Professor S. Murat (Eskisehir, TR)
Abstract Slides
Presentation thumbnail
Role of provocation and exercise imaging for the identification of candidates for myosin inhibitors
Doctor J. Erzeel (Genk, BE)
Abstract Slides
Presentation thumbnail
Mavacamten effectiveness and safety in the real-world setting and association with CYP2C19 metaboliser status: data from a canadian prospective registry
Mr S. Moussa (Montreal, CA)
Abstract Slides
Presentation thumbnail
Increased mechanical dispersion during exercise echocardiography is associated with incomplete response to mavacamten in obstructive hypertrophic cardiomyopathy
Doctor I. Cergan (Bucharest, RO)
Abstract Slides

Access the full session

Session thumbnail
Mapping HCM: from functional assessment to optimised therapy

The Event

Event poster

Heart Failure 2026

11 May 2026 14:30 CET

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources